CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,821 enrolled
Drug / intervention
Etanercept +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01623752
NCT01623752N/ACompleted

A PROSPECTIVE EVALUATION OF THE RADIOGRAPHIC EFFICACY OF ETANERCEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIATIC ARTHRITIS.

Pfizer·observational·Posted Jun 20, 2012·Updated Aug 16, 2019

In Brief

An observational study evaluating Etanercept for Rheumatoid Arthritis and Psoriasis Arthritis. Completed, enrolled 1,821 participants.

Detailed Summary

It is known from the COMET-trial that patients who start Enbrel treatment early have a great chance of reaching clinical remission and radiographic nonprogression. It is still unclear, however, how many patients with early arthritis achieve remission and radiographic nonprogression under the conditions of routine rheumatologic care and the local recommendations of Enbrel treatment (pre-treatment of at least 2 DMARDs, one of them MTX). Therefore, no robust x-ray data are available to show/demonstrate * the average extent of x-ray damage in routine patients on Enbrel outside clinical studies. * if the outstanding effect on structural damage of Enbrel can be reproduced in routine practice. * that the 'Silent Progressor' is an issue relevant not only in clinical trials, but also for day-to-day decision making. * the optimal onset of Enbrel treatment in the course of the disease to prevent radiographic damage

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 20, 2012
Enrollment StartFeb 1, 2012
Primary CompletionMar 1, 2018
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 14.0 years ago

Interventions

Etanerceptdrug

The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.

Etanerceptdrug

The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.